BioCentury
ARTICLE | Clinical News

AVAN begins Phase II cholesterol management trial

August 16, 2001 7:00 AM UTC

Avant (AVAN) began a U.S. placebo-controlled Phase II trial of its CETi-1 cholesterol management vaccine in 200 patients with low HDL levels. The study will assess the safety, immunogenicity and dose-...